Galantamine

"Galantamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.

Descriptor ID

D005702

MeSH Number(s)

D03.132.052.500

D03.438.079.525

Concept/Terms

Galantamine

Razadyne

Galanthamine Hydrobromide

Nivaline

Below are MeSH descriptors whose meaning is more general than "Galantamine".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Amaryllidaceae Alkaloids [D03.132.052]
Galantamine [D03.132.052.500]
Heterocyclic Compounds, 2-Ring [D03.438]
Benzazepines [D03.438.079]
Galantamine [D03.438.079.525]

Below are MeSH descriptors whose meaning is related to "Galantamine".

Below are MeSH descriptors whose meaning is more specific than "Galantamine".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Galantamine" by people in Harvard Catalyst Profiles by year, and whether "Galantamine" was a major or minor topic of these publication.

Bar chart showing 20 publications over 11 distinct years, with a maximum of 3 publications in 2006 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	2	0	2
2006	3	0	3
2007	2	0	2
2008	1	0	1
2009	2	0	2
2011	2	0	2
2013	3	0	3
2015	1	0	1
2018	0	1	1
2019	1	0	1
2020	0	2	2

Below are the most recent publications written about "Galantamine" by people in Profiles.

Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe. Soc Psychiatry Psychiatr Epidemiol. 2021 Mar; 56(3):409-416.

View in: PubMed
Evaluating a longitudinal mediation model of perceived stress, depressive symptoms, and substance use treatment outcomes. Psychol Addict Behav. 2020 Sep; 34(6):660-668.

View in: PubMed
Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacol Biochem Behav. 2019 06; 181:86-92.

View in: PubMed
Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice. J Neuroinflammation. 2018 Apr 18; 15(1):112.

View in: PubMed
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA. 2018 01 09; 319(2):130-142.

View in: PubMed
Efficacy of Cholinesterase Inhibitors in Vascular Dementia: An Updated Meta-Analysis. Eur Neurol. 2016; 75(3-4):132-41.

View in: PubMed
Response to Iraqi and Hughes. J Am Geriatr Soc. 2016 Jan; 64(1):242-3.

View in: PubMed
Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury. Neuropsychopharmacology. 2016 Apr; 41(5):1191-8.

View in: PubMed
Risk of pneumonia in new users of cholinesterase inhibitors for dementia. J Am Geriatr Soc. 2015 May; 63(5):869-76.

View in: PubMed
A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J ECT. 2013 Sep; 29(3):170-8.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

J Am Geriatr Soc
J Clin Psychopharmacol
Dement Geriatr Cogn Disord
Consult Pharm
CNS Neurosci Ther
Clin Interv Aging
Bipolar Disord
Biol Psychiatry
Behav Neural Biol
Am J Manag Care